Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000054.xml
Pharmacopsychiatry 2018; 51(01/02): 5-6
DOI: 10.1055/s-0043-118103
DOI: 10.1055/s-0043-118103
Editorial
Editorial to Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology
Further Information
Publication History
received 31 July 2017
revised 02 August 2017
accepted 04 August 2017
Publication Date:
19 September 2017 (online)
-
References
- 1 Hiemke C, Bergemann N, Clement HW. et al. Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: Update 2017. Pharmacopsychiatry 2018; 51: 9-62
- 2 De Leon J. A Critical Commentary on the 2017 AGNP Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology. Pharmacopsychiatry 2018; 51: 63-68
- 3 Baumann P, Hiemke C, Ulrich S. et al. The AGNP-TDM expert group consensus guidelines: therapeutic drug monitoring in psychiatry. Pharmacopsychiatry 2004; 37: 243-265
- 4 Hiemke C, Baumann P, Bergemann N. et al. AGNP Consensus guidelines for therapeutic drug monitoring in psychiatry: Update 2011. Pharmacopsychiatry 2011; 44: 195-235
- 5 Hicks JK, Bishop JR, Sangkuhl K. et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for cyp2d6 and cyp2c19 genotypes and dosing of selective serotonin reuptake inhibitors. Clin Pharmacol Ther 2015; 98: 127-134
- 6 Gendiagnostik-Kommission. Richtlinie der Gendiagnostik-Kommission (GEKO) für die Beurteilung genetischer Eigenschaften hinsichtlich ihrer Bedeutung für die Wirkung eines Arzneimittels bei einer Behandlung gemäß § 23 Abs. 2 Nr. 1b GenDG. Bundesgesundheitsbl 2017; 60: 472-475 (Available from http://www.rki.de/DE/Content/Kommissionen/GendiagnostikKommission/Richtlinien/RL-WirkungArzneimittel.pdf?__blob=publicationFile [Accessed 07/31/2017])